Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s660, 2025. DOI: 10.25251/1g590e41. Disponível em: https://skin.dermsquared.com/skin/article/view/3833. Acesso em: 23 jan. 2026.